SCHEMBL7127040

SCHEMBL7127040

COc1ccc(C2CCC(OC)CC2C(=O)c2cc(OC)ccc2OC)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
ITK Q08881 1/20 0.40
ALOX15 P16050 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125930 0.93 MAPT (0.46) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL7125560 0.92 MAPT (0.42) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL7127190 0.91 MAPT (0.50) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL7124473 0.91 TUBB1 (0.47) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL6853125 0.91 TUBB4A (0.44) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL6859917 0.90 TUBB4A (0.44) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL7126352 0.89 MAPT (0.41) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL6320947 0.88 MAPT (0.40) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL7127003 0.88 LMNA (0.40) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL6322521 0.87 MAPT (0.40) MAPTKDM4ELMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885KDM4E 1243/4885LMNA 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.